Today's noteworthy downgrades include: ADT Corp. (ADT) downgraded to Neutral from Buy at Citigroup... ANI Pharmaceuticals (ANIP) downgraded to Neutral from Buy at Roth Capital... Altisource Residential (RESI) downgraded to Market Perform at Keefe Bruyette... Apple (AAPL) downgraded at Raymond James on tough comps, Apple (AAPL) Watch risk... BNP Paribas (BNPQY) downgraded to Sell from Hold at Societe Generale... CPFL Energia (CPL) downgraded to Neutral from Buy at UBS... Cabela's (CAB) downgraded to Sell from Neutral at Goldman... Citrix (CTXS) downgraded to Market Perform from Outperform at William Blair... Crown Holdings (CCK) downgraded to Market Perform from Outperform at BMO Capital... Domtar (UFS) downgraded to Market Perform from Outperform at BMO Capital... Extreme Networks (EXTR) downgraded to Hold from Buy at Needham... Hancock Holding (HBHC) downgraded to Sell from Hold at Evercore ISI... Kingfisher (KGFHY) downgraded to Sell from Hold at Societe Generale... Louisiana-Pacific (LPX) downgraded to Neutral from Buy at BofA/Merrill... Perrigo (PRGO) downgraded to Hold from Buy at Argus... Sealed Air (SEE) downgraded to Market Perform from Outperform at BMO Capital... TNT Express (TNTEY) downgraded to Sector Perform from Outperform at RBC Capital... Texas Capital (TCBI) downgraded to Equal Weight from Overweight at Barclays... Tilly's (TLYS) downgraded to Neutral from Buy at B. Riley... Trex Company (TREX) downgraded to Neutral from Buy at SunTrust... Whiting Petroleum (WLL) downgraded to Hold from Buy at Canaccord.

Alphabet (GOOGL), the parent company of Google, is scheduled to report first quarter 2024 results after the market close on Thursday, April 25, with a conference call scheduled for 4:30 pm Eastern Time. What to watch... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Backs FY24 revenue view $4.8B-$5B, consensus $4.92B.

Perrigo announced that pharmaceutical company Esteve Healthcare has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to EUR 275M, consisting of an upfront cash payment of EUR 190M and up to EUR 85M in potential earnout payments based on the Rare Diseases business achieving certain sales milestones. Following the information and consultation process with HRA Pharma Works Council in France, Perrigo would be able to exercise the put option granted by Esteve and enter into a definitive agreement with Esteve for the sale of the Rare Diseases business. The proposed final transaction is expected to close during the third quarter of 2024, subject to the satisfaction of the HRA Works Council consultation and customary closing conditions, including receipt of regulatory approvals.

Apple saw sales of its iPhones fall 19.1% in the first three months of the year, CNBC's Ryan Browne reports, citing data from Counterpoint Research. Meanwhile, Huawei saw a 69.7% surge in smartphone sales in the country during the same period, Counterpoint said. Reference Link